ANI Pharmaceuticals Inc Total Liabilities
ANI Pharmaceuticals Inc total liabilities. Based on the latest financial reports, ANI Pharmaceuticals Inc (ANIP) has total liabilities worth $899.65 Million USD as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. See ANIP days of operational coverage to measure how many days the company can operate on defensive assets alone.
Total Liabilities of ANI Pharmaceuticals Inc (1998–2025)
Total liabilities of ANI Pharmaceuticals Inc from 1998 to 2025. This chart illustrates how ANI Pharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Check ANI Pharmaceuticals Inc (ANIP) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
ANI Pharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of ANI Pharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Greatech Technology Bhd
KLSE:0208
|
Malaysia | RM330.03 Million |
|
Guangdong Goworld Co Ltd
SHE:000823
|
China | CN¥2.66 Billion |
|
Hagerty Inc
NYSE:HGTY
|
USA | $1.36 Billion |
|
Dime Community Bancshares, Inc.
NASDAQ:DCOM
|
USA | $13.50 Billion |
|
Ningbo Haitian Precision Machinery Co Ltd
SHG:601882
|
China | CN¥2.68 Billion |
|
Maxvision Technology Corp
SHE:002990
|
China | CN¥1.10 Billion |
|
FRIEDR.VORW.GRP. ADR/025
F:VH20
|
Germany | €210.59 Million |
|
Fermi Inc.
NASDAQ:FRMI
|
USA | $731.48 Million |
Liability Composition Analysis (1998–2025)
This chart breaks down ANI Pharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see how large is ANI Pharmaceuticals Inc's balance sheet.
Liquidity & Leverage Metrics
ANI Pharmaceuticals Inc Total Liabilities Ratios Explained
ANI Pharmaceuticals Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.71 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.66 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.62 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how ANI Pharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for ANI Pharmaceuticals Inc (1998–2025)
The table below shows the annual total liabilities of ANI Pharmaceuticals Inc from 1998 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $899.65 Million | +5.20% |
| 2024-12-31 | $855.17 Million | +91.39% |
| 2023-12-31 | $446.82 Million | +6.00% |
| 2022-12-31 | $421.55 Million | +2.10% |
| 2021-12-31 | $412.86 Million | +55.51% |
| 2020-12-31 | $265.49 Million | +8.81% |
| 2019-12-31 | $244.00 Million | +4.57% |
| 2018-12-31 | $233.34 Million | -1.70% |
| 2017-12-31 | $237.38 Million | +54.93% |
| 2016-12-31 | $153.22 Million | +22.39% |
| 2015-12-31 | $125.18 Million | +1.02% |
| 2014-12-31 | $123.92 Million | +3402.66% |
| 2013-12-31 | $3.54 Million | -66.60% |
| 2012-12-31 | $10.59 Million | -56.87% |
| 2011-12-31 | $24.56 Million | -4.12% |
| 2010-12-31 | $25.62 Million | +24.33% |
| 2009-12-31 | $20.61 Million | +434.82% |
| 2008-12-31 | $3.85 Million | +154.18% |
| 2007-12-31 | $1.52 Million | -64.74% |
| 2006-12-31 | $4.30 Million | +56.03% |
| 2005-12-31 | $2.76 Million | +44.52% |
| 2004-12-31 | $1.91 Million | +116.38% |
| 2003-12-31 | $881.21K | -29.85% |
| 2002-12-31 | $1.26 Million | +35.40% |
| 2001-12-31 | $927.76K | -1.43% |
| 2000-12-31 | $941.26K | +186.00% |
| 1999-12-31 | $329.12K | -59.76% |
| 1998-12-31 | $817.91K | -- |
About ANI Pharmaceuticals Inc
ANI Pharmaceuticals, Inc., a biopharmaceutical company, develops, manufactures, and markets branded and generic pharmaceutical products in the United States and internationally. The company provides injectables, softgel capsules, and Cortrophin gel, as well as ILUVIEN and YUTIQ products. It also manufactures oral solid dose products, semi-solids, liquids, topicals, controlled substances, and pote… Read more